Diversify Wealth Management LLC Purchases 10,371 Shares of Halozyme Therapeutics, Inc. $HALO

Diversify Wealth Management LLC lifted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 49.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 31,504 shares of the biopharmaceutical company’s stock after acquiring an additional 10,371 shares during the period. Diversify Wealth Management LLC’s holdings in Halozyme Therapeutics were worth $1,987,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in HALO. Arrowstreet Capital Limited Partnership boosted its position in shares of Halozyme Therapeutics by 29.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after acquiring an additional 749,484 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Halozyme Therapeutics by 1.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock valued at $141,613,000 after acquiring an additional 25,731 shares during the last quarter. Norges Bank bought a new stake in Halozyme Therapeutics in the 4th quarter valued at $128,201,000. William Blair Investment Management LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter worth $124,031,000. Finally, Federated Hermes Inc. lifted its stake in Halozyme Therapeutics by 8.5% in the 4th quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock worth $105,972,000 after purchasing an additional 123,917 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Morgan Stanley cut their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Finally, Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $76.11 on Tuesday. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. Halozyme Therapeutics, Inc. has a 1-year low of $55.64 and a 1-year high of $82.26. The firm has a market capitalization of $9.03 billion, a P/E ratio of 27.38, a price-to-earnings-growth ratio of 0.32 and a beta of 0.84. The company’s 50-day moving average is $71.14 and its 200 day moving average is $69.98.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The business had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business’s revenue was up 42.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Research analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In other news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. The trade was a 33.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75. Following the sale, the director directly owned 42,044 shares of the company’s stock, valued at approximately $3,225,195.24. The trade was a 3.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 74,102 shares of company stock worth $5,205,798 over the last three months. 2.50% of the stock is owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.